• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罕见遗传性疾病治疗的新曙光:成骨不全性骨纤维发育异常的“可成药”未来。

The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.

机构信息

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16132 Genoa, Italy.

UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

出版信息

Int J Mol Sci. 2018 Mar 26;19(4):989. doi: 10.3390/ijms19040989.

DOI:10.3390/ijms19040989
PMID:29587443
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5979309/
Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic condition characterized by progressive extra-skeletal ossification leading to cumulative and severe disability. FOP has an extremely variable and episodic course and can be induced by trauma, infections, iatrogenic harms, immunization or can occur in an unpredictable way, without any recognizable trigger. The causative gene is , encoding the Alk-2 type I receptor for bone morphogenetic proteins (BMPs). The signaling is initiated by BMP binding to a receptor complex consisting of type I and II molecules and can proceed into the cell through two main pathways, a canonical, SMAD-dependent signaling and a p38-mediated cascade. Most FOP patients carry the recurrent R206H substitution in the receptor Glycine-Serine rich (GS) domain, whereas a few other mutations are responsible for a limited number of cases. Mutations cause a dysregulation of the downstream BMP-dependent pathway and make mutated ACVR1 responsive to a non-canonical ligand, Activin A. There is no etiologic treatment for FOP. However, many efforts are currently ongoing to find specific therapies targeting the receptor activity and the downstream aberrant pathway at different levels or targeting cellular components and/or processes that are important in modifying the local environment leading to bone neo-formation.

摘要

进行性骨化性纤维发育不良(FOP)是一种罕见的遗传性疾病,其特征是进行性的骨骼外骨化,导致进行性累积和严重残疾。FOP 的病程极其多变且呈间歇性,可由创伤、感染、医源性损伤、免疫接种诱发,也可无明显诱因突发。致病基因为 ,编码骨形态发生蛋白(BMPs)的 Alk-2 型 I 受体。信号由 BMP 与由 I 型和 II 型分子组成的受体复合物结合起始,并可通过两条主要途径进入细胞,即经典的 SMAD 依赖性信号通路和 p38 介导的级联反应。大多数 FOP 患者携带受体甘氨酸-丝氨酸丰富(GS)结构域中反复出现的 R206H 取代,而其他一些突变则导致少数病例发生。突变导致下游 BMP 依赖性途径失调,使突变型 ACVR1 对非经典配体激活素 A 产生反应。目前尚无针对 FOP 的病因治疗方法。然而,目前正在进行许多努力,以寻找针对受体活性和下游异常途径的特定治疗方法,这些方法可在不同水平上靶向细胞成分和/或过程,从而改变导致新骨形成的局部环境。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/031c/5979309/1edf3a0a2546/ijms-19-00989-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/031c/5979309/1edf3a0a2546/ijms-19-00989-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/031c/5979309/1edf3a0a2546/ijms-19-00989-g001.jpg

相似文献

1
The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.罕见遗传性疾病治疗的新曙光:成骨不全性骨纤维发育异常的“可成药”未来。
Int J Mol Sci. 2018 Mar 26;19(4):989. doi: 10.3390/ijms19040989.
2
Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.成纤维细胞生长因子受体 1 型突变型骨化性纤维发育不良 BMP 受体在斑马鱼中 GS 结构域丝氨酸/苏氨酸需求减少。
J Bone Miner Res. 2023 Sep;38(9):1364-1385. doi: 10.1002/jbmr.4869. Epub 2023 Jul 17.
3
The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.在进行性骨化性纤维发育不良中发现的ACVR1 R206H突变通过BMP介导的SMAD1/5/8信号通路增加人诱导多能干细胞衍生的内皮细胞形成和胶原蛋白生成。
Stem Cell Res Ther. 2016 Aug 17;7(1):115. doi: 10.1186/s13287-016-0372-6.
4
ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.ACVR1基因R206H受体突变通过赋予对激活素A的反应性导致进行性骨化性纤维发育不良。
Sci Transl Med. 2015 Sep 2;7(303):303ra137. doi: 10.1126/scitranslmed.aac4358.
5
High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.ACVR1转录调节剂的高通量筛选:进行性骨化性纤维发育不良潜在治疗方法的发现
Dis Model Mech. 2016 Jun 1;9(6):685-96. doi: 10.1242/dmm.023929. Epub 2016 Apr 28.
6
Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.激活素受体1型在进行性骨化性纤维发育不良中的新功能
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15438-43. doi: 10.1073/pnas.1510540112. Epub 2015 Nov 30.
7
Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).激活素 A 放大失调的 BMP 信号,并诱导进行性骨化性纤维发育不良(FOP)患者的原始结缔组织祖细胞向软骨骨分化。
Bone. 2018 Apr;109:218-224. doi: 10.1016/j.bone.2017.11.014. Epub 2017 Nov 21.
8
The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response.进行性骨化性纤维发育不良(FOP)中激活素受体1型(ACVR1)的p.R206H突变导致配体反应改变。
Cell Signal. 2017 Jan;29:23-30. doi: 10.1016/j.cellsig.2016.10.001. Epub 2016 Oct 4.
9
A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene.一例与 ACVR1 基因新型变异相关的进行性骨化性纤维发育不良。
Mol Genet Genomic Med. 2021 Oct;9(10):e1774. doi: 10.1002/mgg3.1774. Epub 2021 Aug 4.
10
Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1 -Specific Human Cellular and Zebrafish Models.全外显子测序鉴定的骨形态发生蛋白(BMP)通路变异在迟发性进行性骨化性纤维发育不良(FOP)患者中的功能检测:使用 ACVR1 特异性人细胞和斑马鱼模型。
J Bone Miner Res. 2022 Nov;37(11):2058-2076. doi: 10.1002/jbmr.4711. Epub 2022 Nov 15.

引用本文的文献

1
Antisense oligonucleotides and their applications in rare neurological diseases.反义寡核苷酸及其在罕见神经系统疾病中的应用。
Front Neurosci. 2024 Sep 23;18:1414658. doi: 10.3389/fnins.2024.1414658. eCollection 2024.
2
How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.激活素 A 如何成为进行性骨化性纤维发育不良的治疗靶点。
Biomolecules. 2024 Jan 12;14(1):101. doi: 10.3390/biom14010101.
3
Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers.

本文引用的文献

1
Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressiva.激活素依赖性信号在纤维/脂肪祖细胞中引起进行性骨化性纤维发育不良。
Nat Commun. 2018 Feb 2;9(1):471. doi: 10.1038/s41467-018-02872-2.
2
Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.与生物制药公司互动的原则:为罕见病领域的患者倡导组织制定指南。
Orphanet J Rare Dis. 2018 Jan 22;13(1):18. doi: 10.1186/s13023-018-0761-2.
3
Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
探索进行性骨化性纤维发育不良的复杂领域:从现有范式到治疗前沿。
Genes (Basel). 2023 Nov 30;14(12):2162. doi: 10.3390/genes14122162.
4
Fibrodysplasia ossificans progressiva: A rare disease with spinal deformity and severe hip dysfunction.进行性骨化性纤维发育不良:一种伴有脊柱畸形和严重髋关节功能障碍的罕见疾病。
Front Pediatr. 2022 Sep 15;10:981372. doi: 10.3389/fped.2022.981372. eCollection 2022.
5
Fibrodysplasia Ossificans Progressiva: A Report of Four Cases.进行性骨化性纤维发育不良:4例报告
Cureus. 2022 Mar 22;14(3):e23392. doi: 10.7759/cureus.23392. eCollection 2022 Mar.
6
Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification.血管壁中肌肉抑制素/激活素-A 信号转导与血管钙化。
Cells. 2021 Aug 12;10(8):2070. doi: 10.3390/cells10082070.
7
A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene.一例与 ACVR1 基因新型变异相关的进行性骨化性纤维发育不良。
Mol Genet Genomic Med. 2021 Oct;9(10):e1774. doi: 10.1002/mgg3.1774. Epub 2021 Aug 4.
8
Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.进行性骨化性纤维发育不良:从基础到临床的最新概念。
Dis Model Mech. 2020 Sep 21;13(9):dmm046441. doi: 10.1242/dmm.046441.
9
Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish.进行性骨化性纤维发育不良突变型 ACVR1 在发育中的斑马鱼中通过多种方式发出信号。
Elife. 2020 Sep 8;9:e53761. doi: 10.7554/eLife.53761.
10
Clinical Aspects and Current Therapeutic Approaches for FOP.进行性骨化性纤维发育不良的临床特征与当前治疗方法
Biomedicines. 2020 Sep 2;8(9):325. doi: 10.3390/biomedicines8090325.
人类纤维发育不良性骨化性纤维瘤(FOP)中 BMP 受体变异导致的 BMP 配体非依赖性受体激活在斑马鱼中显现。
Bone. 2018 Apr;109:225-231. doi: 10.1016/j.bone.2018.01.002. Epub 2018 Jan 4.
4
ECSIT links TLR and BMP signaling in FOP connective tissue progenitor cells.ECSIT 在 FOP 结缔组织祖细胞中连接 TLR 和 BMP 信号通路。
Bone. 2018 Apr;109:201-209. doi: 10.1016/j.bone.2017.12.024. Epub 2017 Dec 27.
5
Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.成骨不全性骨形成不全进展期患者中急性和慢性雷帕霉素的应用:两例报告。
Bone. 2018 Apr;109:281-284. doi: 10.1016/j.bone.2017.12.011. Epub 2017 Dec 11.
6
Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1 Mouse Model of Fibrodysplasia Ossificans Progressiva.破骨细胞和巨噬细胞耗竭可损害 Acvr1 小鼠纤维性骨发育不良进展性异位骨化模型中的异位骨化。
J Bone Miner Res. 2018 Feb;33(2):269-282. doi: 10.1002/jbmr.3304. Epub 2018 Jan 3.
7
Peripheral Blood Mononuclear Cell Immunophenotyping in Fibrodysplasia Ossificans Progressiva Patients: Evidence for Monocyte DNAM1 Up-regulation.进行性骨化性纤维发育不良患者外周血单个核细胞免疫表型分析:单核细胞 DNAM1 上调的证据。
Cytometry B Clin Cytom. 2018 Jul;94(4):613-622. doi: 10.1002/cyto.b.21594. Epub 2017 Nov 15.
8
Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.ALK2 型骨形态发生蛋白受体激酶强效和高选择性配体 LDN-212854 的结构基础
Bone. 2018 Apr;109:251-258. doi: 10.1016/j.bone.2017.09.004. Epub 2017 Sep 12.
9
Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).肥大细胞抑制作为进行性骨化性纤维发育不良(FOP)的治疗方法。
Bone. 2018 Apr;109:259-266. doi: 10.1016/j.bone.2017.08.023. Epub 2017 Aug 26.
10
Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.视黄酸在骨骼发育和生长中的作用和作用为正在进行的异位骨化预防试验提供了依据。
Bone. 2018 Apr;109:267-275. doi: 10.1016/j.bone.2017.08.010. Epub 2017 Aug 19.